Ontology highlight
ABSTRACT: Background
Cell-based therapies are being developed to meet the need for curative therapy in chronic kidney disease (CKD). Bone marrow- (BM-) derived mesenchymal stromal cells (MSCs) enhance tissue repair and induce neoangiogenesis through paracrine action of secreted proteins and extracellular vesicles (EVs). Administration of allogeneic BM MSCs is less desirable in a patient population likely to require a kidney transplant, but potency of autologous MSCs should be confirmed, given previous indications that CKD-induced dysfunction is present. While the immunomodulatory capacity of CKD BM MSCs has been established, it is unknown whether CKD affects wound healing and angiogenic potential of MSC-derived CM and EVs.Methods
MSCs were cultured from BM obtained from kidney transp
SUBMITTER: van Rhijn-Brouwer FCC
PROVIDER: S-EPMC6942892 | biostudies-literature | 2019
REPOSITORIES: biostudies-literature